21 stories found
Several companies, including Biofrontera, Lamar Advertising, Frontdoor, and Peloton, have released their second-quarter 2026 earnings reports and corresponding call transcripts. These releases provide financial updates and insights into their performance.
Collegium Pharmaceutical Inc. (COLL) stock is attracting investor interest, primarily due to its portfolio of medications for Attention-Deficit/Hyperactivity Disorder (ADHD).
Several companies, including ATN International, EVERTEC, Montrose Environmental, Phibro Animal, UGI, and TKO, have released their latest quarterly financial results. While some companies reported earnings that beat analyst expectations, others missed revenue or EPS forecasts.
The CEO of Visteon has sold 49,000 shares of the company's stock, totaling $4.6 million, prompting investors to assess the implications.
Collegium Pharmaceutical announced record performance for 2025 and anticipates JORNAY PM will be a key driver for growth in 2026, as presented at the Barclays Miami Conference.
An earnings preview for Collegium Pharmaceutical's fourth quarter of 2025 details expectations prior to the official release.
This article provides a summary of Collegium Pharmaceutical, Inc.'s earnings call for the second quarter of 2026.
Collegium Pharmaceutical, Inc. provided a summary of its Q1 2026 earnings call, detailing its financial results and future projections.
Collegium Pharmaceutical provided its 2026 revenue outlook and elaborated on a $650 million AZSTARYS deal during the Needham Conference.
Collegium Pharmaceutical (COLL) experienced a surge in its stock price following the announcement of record quarterly results.
Collegium Pharmaceutical has released highlights from its fourth-quarter earnings call, providing an overview of its financial results.
Boston Legacy FC has announced a sponsorship with Collegium Pharmaceutical for a new sensory room, enhancing accessibility for fans.
Krispy Kreme and Collegium Pharmaceutical have both released highlights from their respective second-quarter earnings calls. These summaries provide key financial updates from both companies.
Several companies, including RXO, Collegium Pharmaceutical, and Arrow Electronics, released their Q1 or Q2 earnings reports. Some firms reported results that beat analyst expectations for revenue and non-GAAP EPS.
An analysis evaluates whether Collegium Pharmaceutical stands out as one of the top small-cap drug manufacturers.
Collegium Pharmaceutical plans to acquire the ADHD medication Azstarys in a deal valued at up to $785 million, expanding its portfolio in the neuroscience therapeutic area.
Collegium Pharmaceuticals aims for a 31% revenue increase for its drug Jornay by 2026, alongside efforts to enhance the durability of its pain management portfolio.
Collegium Pharmaceutical reported Non-GAAP EPS of $2.04, missing estimates by $0.10, and revenue of $205.4 million, which also missed expectations by $0.96 million.
Collegium Pharmaceutical is experiencing increased momentum, driven by its product Jornay PM, with Truist analysts highlighting the company's strong pain portfolio.